MindWalk (NASDAQ:HYFT) Stock Rating Lowered by Wall Street Zen

MindWalk (NASDAQ:HYFT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other brokerages also recently commented on HYFT. HC Wainwright reissued a “buy” rating on shares of MindWalk in a research note on Monday. JonesTrading began coverage on MindWalk in a research report on Thursday, April 16th. They set a “buy” rating and a $5.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.00.

MindWalk Stock Performance

NASDAQ HYFT opened at $1.36 on Friday. The company has a quick ratio of 3.64, a current ratio of 2.80 and a debt-to-equity ratio of 0.26. The stock has a market cap of $63.53 million, a P/E ratio of -6.18 and a beta of 0.83. The firm’s 50-day simple moving average is $1.56. MindWalk has a one year low of $0.99 and a one year high of $3.25.

MindWalk (NASDAQ:HYFT) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%.The business had revenue of $3.03 million during the quarter. Equities analysts expect that MindWalk will post -0.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC grew its position in shares of MindWalk by 147.3% in the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after buying an additional 96,018 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in MindWalk during the fourth quarter valued at approximately $91,000. XTX Topco Ltd boosted its stake in MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after acquiring an additional 44,331 shares in the last quarter. Virtu Financial LLC acquired a new stake in MindWalk in the fourth quarter valued at approximately $51,000. Finally, Bank of Montreal Can grew its holdings in MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after purchasing an additional 24,500 shares during the last quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.